There has been some selling insider activity on SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) recently. President & CEO Friedhelm Blobel let go of 39,656 shares at a price of $10.52 on Thu the 8th. The President & CEO now owns $981,505 of the stock as reported to the SEC. Friedhelm Blobel, President & CEO reported the sale of 10,300 shares of SCLN stock. The shares were sold on June 6th for a price of $10.00. The President & CEO now owns $932,990 of the stock according to the SEC filing.
President & CEO Friedhelm Blobel sold 21,464 shares at a price of $9.34 on Wed the 24th. Blobel now owns $864,193 of stock per an SEC filing yesterday.
SciClone Pharmaceuticals, Inc. (SciClone), launched on June 26, 2003, is a pharmaceutical company. The Business’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Business’s business is focused primarily in the People’s Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong. The Business’s lead product ZADAXIN (thymalfasin) is approved in over 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and certain cancers according to the local regulatory approvals, and for use as an immune system enhancer. In addition to ZADAXIN, SciClone markets seven partnered and in-licensed products in China. The Company sells ZADAXIN in various international markets through its subsidiary, SciClone Pharmaceuticals International Ltd. (SPIL)..
Here are a few other firms who have also updated their positions. As of quarter end Morgan Stanley had sold 300 shares trimming its position 33.0%. The value of the investment in SCLN decreased from $10,000 to $6,000 a change of $4,000 quarter to quarter. As of the end of the quarter Goldman Sachs Group Inc had disposed of a total of 54,469 shares trimming its holdings by 41.4%. The value of the investment in SciClone Pharmaceuticals, Inc. went from $1,420,000 to $755,000 decreasing 46.8% for the reporting period.
As of the end of the quarter Ranger Investment Management, L.p. had acquired a total of 27,590 shares growing its stake by 23.8%. The value of the total investment in SciClone Pharmaceuticals, Inc. went from $1,249,000 to $1,404,000 a change of 12.4% quarter over quarter. As of the end of the quarter Macquarie Group Ltd had sold 8,300 shares trimming its position 64.8%. The value in dollars went from $138,000 to $44,000 a change of 68.1% since the last quarter.
On November 29 analysts at Maxim Group began coverage giving it an initial rating of “Buy”. On June 29, 2015 MLV & Co. issued its first research report on the stock with a rating of “Buy” and projecting a price target of $15.00.
On November 14 the company was rated “Hold” in a report from BWS Financial which is down from the previous “Buy” rating.
The company is down since yesterday’s close of $10.9. Shares of the company are trading at $10.85 just a bit higher than the 50 day moving average of $9.70 and which is just a bit higher than the 200 day moving average of $9.95. The 50 day moving average was up by +11.86% and the 200 day average went up $0.90 or +9.02%.
SciClone Pharmaceuticals, Inc.’s P/E ratio is 15.26 and the market cap of the company is 561.29M. In the last earnings report the EPS was $0.71 and is estimated to be $0.92 for the current year with 51,732,000 shares currently outstanding. Next quarter’s EPS is estimated at $0.22 with next year’s EPS projected to be $1.09.
Short traders are more bullish on SciClone Pharmaceuticals, Inc. of late looking at the fall in short interest. The firm saw a fall in short interest between April 28, 2017 and May 15, 2017 of -2.42%. Short interest decreased from 1,531,612 to 1,494,484 over that timeframe. Days to cover increased from 6.6 to 6.7 and the percentage of shorted shares is 0.03% as of May 15.